Welcome to our dedicated page for Eupraxia Pharmaceuticals news (Ticker: EPRX), a resource for investors and traders seeking the latest updates and insights on Eupraxia Pharmaceuticals stock.
Eupraxia Pharmaceuticals Inc. develops locally delivered, extended-release drug candidates using its proprietary Diffusphere technology, a polymer-based microsphere platform for targeted, controlled delivery. The company's news centers on clinical development of EP-104GI in eosinophilic esophagitis and EP-104IAR in knee osteoarthritis pain, including RESOLVE trial data, tissue-health and symptom measures, endoscopic and histologic scoring, and scientific conference presentations.
Recurring updates also cover financial results, clinical-supply and balance-sheet commentary, investor conference activity, and governance changes as Eupraxia advances its gastrointestinal and pain-focused development programs on Nasdaq and the TSX under EPRX.
Eupraxia Pharmaceuticals (TSX: EPRX, NASDAQ: EPRX) announced that it will present initial results from its ongoing Phase 1b study of EP-104GI at the Digestive Disease Week (DDW) Annual Meeting 2024, held in Washington, D.C., from May 18-21, 2024.
The study focuses on treating eosinophilic esophagitis using EP-104GI, a long-acting injectable suspension of fluticasone propionate. Chief Scientific Officer Amanda Malone, PhD, will deliver a poster presentation on May 18, 2024.
The presentation details are: Abstract: 4031521, Session Type: Poster Session, Session Title: Eosinophilic Esophagitis and Gastroenteritis: Clinical, and Session Date & Time: May 18, 2024, from 12:30 PM to 1:30 PM EDT (UTC –4).
Further details will be available on Eupraxia's website.
Eupraxia Pharmaceuticals reported its first quarter 2024 financial results and provided a corporate update, highlighting achievements such as listing on Nasdaq, progress in clinical studies, and financial performance. Notable milestones include the presentation of positive clinical data, initiation of Phase 3 development programs, and securing funding through public offerings. The company's focus on optimizing drug delivery technology and advancing treatments for conditions like osteoarthritis shows promise for future growth and development.
Eupraxia Pharmaceuticals has announced the formation of a Clinical Advisory Board for its gastrointestinal program, specifically focusing on the EoE treatment. The board consists of renowned experts in the field who will guide the development of EP-104GI for eosinophilic esophagitis. The company aims to address the unmet medical needs of the EoE patient population with their proprietary DiffuSphere™ technology.
Summary not available.
Summary not available.
Summary not available.
Summary not available.